Ramelteon: interakcje

Alcohol: Causes additive psychomotor impairment; should not be used in combination. (etykieta leku Ramelteon, Interakcje z innymi lekami)

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (etykieta leku Alprazolam, Ostrzeżenia i środki ostrożności)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (etykieta leku Azelastyna + flutykazon, Ostrzeżenia i środki ostrożności)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Buprenorfina, Ostrzeżenie w ramce)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Butalbital + kwas acetylosalicylowy + kofeina + kodeina, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Butalbital + paracetamol + kofeina + kodeina, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Butorfanol, Ostrzeżenie w ramce)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (etykieta leku Cetyryzyna, Ostrzeżenia i środki ostrożności)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Chlordiazepoksyd, Ostrzeżenia)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Chlordiazepoksyd + klidynium, Ostrzeżenia)

…have a breathing problem such as emphysema or chronic bronchitis glaucoma trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers When using this product excitability may occur, especially in children drowsiness may occur avoid alcoholic beverages alchohol, sedatives and tranquilizers… (etykieta leku Chlorfenamina, Ostrzeżenia)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (etykieta leku Chlorpromazyna, Przeciwwskazania)

Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (etykieta leku Cyklobenzapryna, Interakcje z innymi lekami)

Fluvoxamine (strong CYP1A2 inhibitor): Increases AUC for ramelteon and should not be used in combination. (etykieta leku Ramelteon, Przeciwwskazania)

Fluvoxamine (strong CYP1A2 inhibitor): Increases AUC for ramelteon and should not be used in combination. (etykieta leku Ramelteon, Przeciwwskazania)

…modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which… (etykieta leku Darunawir, Przeciwwskazania)

…modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is contraindicated in patients receiving certain co-administered drugs for which altered plasma concentrations… (etykieta leku Darunawir + kobicystat, Przeciwwskazania)

Fluvoxamine (strong CYP1A2 inhibitor): Increases AUC for ramelteon and should not be used in combination. (etykieta leku Ramelteon, Przeciwwskazania)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Diazepam, Ostrzeżenia)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (etykieta leku Difenoksylat + atropina, Przeciwwskazania)

…breathing problem such as emphysema or chronic bronchitis • glaucoma • trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking • a sedative or any other sleep-aid • tranquilizers • any other antihistamines • any other drugs When using this product • avoid alcoholic beverages • do not drive a motor vehicle or operate… (etykieta leku Doksylamina, Ostrzeżenia)

Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (etykieta leku Doksylamina + pirydoksyna, Ostrzeżenia i środki ostrożności)

…Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly dependent on CYP3A for clearance and for which… (etykieta leku Elwitegrawir + kobicystat + emtrycytabina + tenofowir, Przeciwwskazania)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (etykieta leku Eszopiklon, Ostrzeżenia i środki ostrożności)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (etykieta leku Fenelzyna, Przeciwwskazania)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Fentanyl, Ostrzeżenie w ramce)

CONTRAINDICATIONS Phenothiazines are contraindicated in patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. (etykieta leku Flufenazyna, Przeciwwskazania)

Patients should not take ROZEREM in conjunction with fluvoxamine [see Drug Interactions (7) ] . (etykieta leku Ramelteon, Przeciwwskazania)

…Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (etykieta leku Fosamprenawir, Przeciwwskazania)

• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (etykieta leku Gabapentyna, Ostrzeżenia i środki ostrożności)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Hydrokodon, Ostrzeżenie w ramce)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (etykieta leku Hydrokodon + chlorfenamina, Ostrzeżenie w ramce)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (etykieta leku Hydrokodon + homatropina, Ostrzeżenie w ramce)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (etykieta leku Hydrokodon + ibuprofen, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Hydrokodon + paracetamol, Ostrzeżenie w ramce)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (etykieta leku Hydroksyzyna, Środki ostrożności)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (etykieta leku Hydromorfon, Ostrzeżenie w ramce)

Fluvoxamine (strong CYP1A2 inhibitor): Increases AUC for ramelteon and should not be used in combination. (etykieta leku Ramelteon, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (etykieta leku Karbinoksamina, Ostrzeżenia i środki ostrożności)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (etykieta leku Ketamina, Interakcje z innymi lekami)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (etykieta leku Ketokonazol, Przeciwwskazania)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Klobazam, Ostrzeżenia i środki ostrożności)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Klonazepam, Ostrzeżenia)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (etykieta leku Klonidyna, Ostrzeżenia i środki ostrożności)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Klorazepan, Ostrzeżenia)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Kodeina, Ostrzeżenie w ramce)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (etykieta leku Lewocetyryzyna, Ostrzeżenia i środki ostrożności)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Leworfanol, Ostrzeżenie w ramce)

…Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma concentrations… (etykieta leku Lopinawir + rytonawir, Przeciwwskazania)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (etykieta leku Lorazepam, Ostrzeżenia i środki ostrożności)

Fluvoxamine (strong CYP1A2 inhibitor): Increases AUC for ramelteon and should not be used in combination. (etykieta leku Ramelteon, Przeciwwskazania)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (etykieta leku Metadon, Ostrzeżenie w ramce)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (etykieta leku Metaksalon, Ostrzeżenia i środki ostrożności)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (etykieta leku Midazolam, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Morfina, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Nalbufina, Ostrzeżenie w ramce)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (etykieta leku Nalmefen, Ostrzeżenia i środki ostrożności)

…(selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin • Vasopressin receptor antagonists: tolvaptan ➢ Drugs that… (etykieta leku Nirmatrelwir + rytonawir, Przeciwwskazania)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Oksazepam, Ostrzeżenia)

• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (etykieta leku Oksybat sodu, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Oksykodon, Ostrzeżenie w ramce)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (etykieta leku Oksykodon + paracetamol, Ostrzeżenie w ramce)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Oksymorfon, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Olicerydyna, Ostrzeżenie w ramce)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (etykieta leku Olopatadyna, Ostrzeżenia i środki ostrożności)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (etykieta leku Olopatadyna + mometazon, Ostrzeżenia i środki ostrożności)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Paracetamol + kodeina, Ostrzeżenie w ramce)

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (etykieta leku Pentazocyna + nalokson, Ostrzeżenie w ramce)

CONTRAINDICATIONS Perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown… (etykieta leku Perfenazyna, Przeciwwskazania)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Petydyna, Ostrzeżenie w ramce)

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (etykieta leku Pokrzyk wilcza jagoda (belladonna) + opium, Ostrzeżenie w ramce)

• Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (etykieta leku Pregabalina, Ostrzeżenia i środki ostrożności)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). Do not use in pediatric surgery. (etykieta leku Prochlorperazyna, Przeciwwskazania)

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (etykieta leku Prometazyna + kodeina, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Remifentanyl, Ostrzeżenie w ramce)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (etykieta leku Rytonawir, Ostrzeżenie w ramce)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Tapentadol, Ostrzeżenie w ramce)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Tramadol, Ostrzeżenie w ramce)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etykieta leku Tramadol + paracetamol, Ostrzeżenie w ramce)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (etykieta leku Triazolam, Ostrzeżenia i środki ostrożności)

CONTRAINDICATIONS A known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and preexisting liver damage. (etykieta leku Trifluoperazyna, Przeciwwskazania)

Fluvoxamine (strong CYP1A2 inhibitor): Increases AUC for ramelteon and should not be used in combination. (etykieta leku Ramelteon, Przeciwwskazania)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (etykieta leku Zaleplon, Ostrzeżenia)

Fluvoxamine (strong CYP1A2 inhibitor): Increases AUC for ramelteon and should not be used in combination. (etykieta leku Ramelteon, Przeciwwskazania)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (etykieta leku Zolpidem, Ostrzeżenia i środki ostrożności)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (etykieta leku Allopurynol, Ostrzeżenia i środki ostrożności)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (etykieta leku Aminofilina, Interakcje z innymi lekami)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (etykieta leku Biktegrawir + emtrycytabina + alafenamid tenofowiru, Interakcje z innymi lekami)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Use with CNS depressants may result in an additive or potentiating effect. (etykieta leku Brymonidyna, Interakcje z innymi lekami)

Use with CNS depressants may result in an additive or potentiating effect. (etykieta leku Brymonidyna + tymolol, Interakcje z innymi lekami)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Bupiwakaina, Ostrzeżenia i środki ostrożności)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Bupiwakaina + adrenalina, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (etykieta leku Buspiron, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (etykieta leku Deutetrabenazyna, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Doxepin: Increases systemic exposure of ramelteon; patients should be closely monitored when ramelteon is coadministered with doxepin. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Donepezil: Increases systemic exposure of ramelteon; patients should be closely monitored when ramelteon is coadministered with donepezil. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Lidokaina + adrenalina, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Donepezil: Increases systemic exposure of ramelteon; patients should be closely monitored when ramelteon is coadministered with donepezil. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (etykieta leku Metyrozyna, Interakcje z innymi lekami)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (etykieta leku Nalokson, Ostrzeżenia i środki ostrożności)

…malformation, central nervous system tumor or infection, or metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia) excessive use of alcohol or sedatives, addiction to cocaine or stimulants, or withdrawal from sedatives patients with diabetes treated with insulin and/or oral diabetic medications (sulfonylureas and meglitinides)… (etykieta leku Naltrekson + bupropion, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (etykieta leku Teofilina, Interakcje z innymi lekami)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Excessive reduction of blood glucose (additive effect) f CNS depressant agents (including opioids, alcohol, sedatives, hypnotics) Use with caution d Increased CNS depression Dietary supplements containing sympathomimetics Contraindicated a Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs)… (etykieta leku Tranylcypromina, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (etykieta leku Triheksyfenidyl, Interakcje z innymi lekami)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (etykieta leku Trimetobenzamid, Ostrzeżenia i środki ostrożności)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etykieta leku Ramelteon, Interakcje z innymi lekami)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (etykieta leku Bupropion, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (etykieta leku Doksapram, Ostrzeżenia)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etykieta leku Epoetyna alfa, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (etykieta leku Prazosyna, Interakcje z innymi lekami)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (etykieta leku Montelukast, Interakcje z innymi lekami)